Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy. For the treatment of febrile episodes in neutropenic patients

PharmacoEconomics
J A PaladinoR Ramphal

Abstract

To assess the relative cost effectiveness of cephalosporin monotherapy options and aminoglycoside/ureidopenicillin combination therapy for the treatment of febrile episodes in adult patients with neutropenia. This was a retrospective cost-effectiveness analysis conducted from the institutional perspective. The analysis was based on 741 febrile episodes in adult patients with neutropenia enrolled in 5 randomised trials: 3 comparing monotherapy with ceftazidime or cefepime, and 2 comparing cefepime monotherapy versus aminoglycoside/ureidopenicillin combination therapy. Resource utilisation included costs for study antibacterials, treatment of adverse effects and failures, and hospitalisation. The primary end-point was the overall cost of treatment per patient. Cost-effectiveness ratios were also analysed. No significant differences in clinical success rates were detected. Median per-patient costs in the monotherapy comparisons were $US7849 for cefepime and $US7788 for ceftazidime [1997 values; not significantly different (NS)]. Corresponding costs for the monotherapy versus combination therapy comparisons were $US9780 for cefepime and $US10 159 for gentamicin/ureidopenicillin (NS). Despite a higher acquisition cost for cefepime, ...Continue Reading

References

Jan 1, 1978·Medical and Pediatric Oncology·P A PizzoA S Levine
Mar 1, 1984·The American Journal of Medicine·A E Brown
May 1, 1995·The Medical Clinics of North America·H Giamarellou
Mar 1, 1995·The American Journal of Medicine·E J Anaissie, S Vadhan-Raj
Jan 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P Y BochudP Francioli
May 6, 1993·The New England Journal of Medicine·P A Pizzo
Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P S McKinnonA W Karchmer
Oct 6, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W T HughesL S Young
Mar 9, 1993·PharmacoEconomics·D A Katz, H G Welch

❮ Previous
Next ❯

Citations

Apr 30, 2003·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·V C CostaJ W Rogerio
Dec 9, 2004·Pharmacotherapy·Joseph A Paladino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.